Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330

Table 1

Patient and tumor characteristics for cohort A and B patients in RTOG 0330.

	Cohort A; (𝑛=15)	Cohort B; (𝑛=7)
Median age (years)	49 (range 20–75)	47 (range 39–81)
Gender
Male	8 (53.3%)	5 (71.4%)
Female	7 (46.7%)	2 (28.6%)
Median tumor size (cm)	12.8; (range 8.4–16.7)	10.0; (range 5.6–27.0)
Tumor site
Upper extremity	1 (6.7%)	0 (0.0%)
Lower extremity	11 (73.3%)	5 (71.4%)
Buttock/hip	2 (13.3%)	1 (14.3%)
Abdominal wall	0 (0.0%)	1 (14.3%)
Back	1 (6.7%)	0 (0.0%)
Histology
Liposarcoma	2 (13.3%)	3 (42.9%)
MFH	4 (26.7%)	0 (0.0%)
Synovial	2 (13.3%)	2 (28.6%)
MPNST	3 (20.0%)	0 (0.0%)
Other	4 (26.7%)	2 (28.6%)

MFH: malignant fibrous histiocytoma; MPNST: malignant peripheral nerve sheath tumor.